Please login to the form below

Not currently logged in
Email:
Password:

anti-PD-1

This page shows the latest anti-PD-1 news and features for those working in and with pharma, biotech and healthcare.

BMS to test Vedanta’s bacterial therapy with Opdivo

BMS to test Vedanta’s bacterial therapy with Opdivo

Squibb’s PD-1 inhibitor Opdivo. ... In animal studies presented at this year’s Society for Immunotherapy of Cancer (SITC) meeting, VE800 on its own and alongside PD-1 inhibitors showed anti-tumour effects, including cytotoxic T

Latest news

  • Analysts lukewarm on GSK’s new cancer acquisition Analysts lukewarm on GSK’s new cancer acquisition

    Lynparza’s presence is looming again, however, with first-line maintenance data of its own from the PAOLA-1 trial due in 2019. ... He does feel there is potential to position Zejula as combination therapy with checkpoint inhibitors, including

  • AZ’s MYSTIC survival data is in – and it’s a bust AZ’s MYSTIC survival data is in – and it’s a bust

    There’s no doubt that overall the study is a big disappointment, and will allow Merck &Co’s rival PD-1 inhibitor Keytruda (pembrolizumab) to maintain its fierce grip on the ... We are encouraged to see that Imfinzi monotherapy activity is in-line

  • Keytruda hits survival targets in first-line kidney cancer Keytruda hits survival targets in first-line kidney cancer

    MSD says Keytruda is the first anti-PD-1 drug to improve both OS and PFS in first-line RCC, and that throws down a gauntlet to Merck and its partner ... Pfizer when it presents the JAVELIN Renal 101 study of its PD-1 drug Bavencio (avelumab) plus Inlyta

  • New leader at Medivir after setbacks New leader at Medivir after setbacks

    The HDAC inhibitor class has taken a knock recently, however, after Syndax’s rival entinostat candidate failed to hit the mark in a combination trial with Merck &Co/MSD’s ... PD-1 drug Keytruda (pembrolizumab) in lung cancer.

  • FDA green lights BMS’ Opdivo for ‘hard-to-treat’ small cell lung cancer FDA green lights BMS’ Opdivo for ‘hard-to-treat’ small cell lung cancer

    However, treating the disease from a ‘different angle’, Opdivo can target and block the activity of PD-1, a protein that prevents T cells from recognising and attacking inflamed tissues and ... It’s a significant win for BMS, which is chasing rival

More from news
Approximately 3 fully matching, plus 47 partially matching documents found.

Latest Intelligence

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    We hope to capitalise further on the effects of single agent anti-PD-1/PD-L1 and anti-CTLA-4 monotherapy trials and see even greater survival benefits for patients.”. ... This has shaped industry development strategies, said Stefan Zimmermann. "For

  • Pharma deals continue to slide Pharma deals continue to slide

    Gilead has been trying to diversify away from anti-viral therapies into oncology and Kite is a good fit with its CAR-T technology and a lead product in priority review ... Licence to develop and commercialise. GLS-010, anti-PD-1 antibody in phase I for

  • The new launch paradigm The new launch paradigm

    Thousands of patients worldwide are in clinical trials with anti-PD-1 or anti-PD-L1 drugs produced by several pharmaceutical companies prior to the expected arrival of this new exciting

  • Deal Watch July 2016 Deal Watch July 2016

    At the other end of the development spectrum Servier paid the same amount upfront for the rights to Sorrento's immuno-oncology product: STI-A1110, an anti-PD-1 mAb, presently ... Acquisition. 1, 530. AstraZeneca/ Leo Pharma. Tralokinumab (anti-IL-13) in

  • Deal Watch October 2015 Deal Watch October 2015

    Up to 3 anti-PD-1 based bispecific antibodies for oncology. Expansion of existing collaboration. ... Research collaboration, licence. 535. XOMA Corporation/ Novartis. Anti-transforming growth factor-beta (TGFb) antibody programme incl XOMA089 plus other

More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics